ntroduction: Esophageal squamous cell carcinoma (ESCC) is among the 10 top causes of cancer related death in Iran. Cisplatin (CDDP) is platinum-based chemotherapy medication routinely used for ESCC,although response rate for this anticancer drug isnot considerable.The aim of present study was to determine whether combination of CDDP with ellagic acid derivatives could improve its cytotoxicity in ESCC cells. Methods: urolithin a (UA), urolithin b (UB) and methylated UA (mUA) were synthesized and KYSE30 cells were used as an in vitro model of ESCC. After IC50 values of UA, UB, mUA and CDDP were determined by MTT assay, cells were treated with20 μM of UA, UB or mUAin combination with 1μM CDDP. Then, viability of cells was assed24, 48, 72 and 96 h after treatments. Results: Assessment of cell viabilityindicated that UA increased CDDP toxicity up to 3.81%, 10.23%, 10.64% and 11.47% during 4 consecutive days. In addition, increased efficacy of CDDP by UB were determined as 7.98%, 4.83%, 6.9% and 5.66% during 4 mention periods. Moreover, calculated increased toxicity of CDDP by mUA were as6.33%, 7.56%, 7.02% and 8.47% after 24, 48, 72 and 96 h, respectively.Conclusion: To improve clinical outcome of anticancer agents, combination of drugs is used as adjuvant or neoadjuvantchemotherapy for ESCC. Since non-toxic concentration of ellagic acid derivatives increased cytotoxicity of CDDP, combinatorial effectof these agents could be tested using other chemotherapeutics

Keywords